## Broker Ratings - UK Monday, 22 July, 2013 11:30:00 AM

11:30:00 AW							
						Potential	
				Target		upside/	
Company	Index	Sector	Rating	Price	Last Price	downside	Contributing Broker
MAINTAIN							
African Barrick Gold	FTSE 250	Basic Materials	Outperform	270	109.2	147.3%	RBC Capital Markets
Anglo American	FTSE 100	Basic Materials	Buy	2025.9	1380	46.8%	Investec
Dialight	FTSE SMALLCAP	Industrial	Buy	1450	1089	33.1%	Canaccord Genuity Corp
Prudential	FTSE 100	Financial	Overweight	1443	1154	25.0%	Barclays
Catlin Group Ltd	FTSE 250	Financial	Overweight	637	519	22.7%	Barclays
Vodafone Group	FTSE 100	Communications	Buy	230	192.35	19.6%	Nomura
Barclays	FTSE 100	Financial	Buy	380	321.65	18.1%	Societe Generale
William Hill	FTSE 250	Consumer, Cyclical	Overweight	550	468.2	17.5%	JPMorgan
Amlin	FTSE 250	Financial	Overweight	481	412.9	16.5%	Barclays
Compass Group	FTSE 100	Consumer, Cyclical	Buy	1000	892	12.1%	Deutsche Bank
BG Group	FTSE 100	Energy	Hold	1350	1216.5	11.0%	Societe Generale
Soco International	FTSE 250	Energy	Hold	400	363.2	10.1%	Jefferies
St James's Place	FTSE 250	Financial	Overweight	654	594.5	10.0%	Barclays
Dixons Retail	FTSE 250	Consumer, Cyclical	Hold	48	44.96	6.8%	Numis Securities Ltd
BP	FTSE 100	Energy	Hold	500	468.4	6.7%	Societe Generale
Shire	FTSE 100	Consumer, Non-cyclical	Overweight	2325	2240	3.8%	Barclays
Intermediate Capital Group	FTSE 250	Financial	Add	500	490.5	1.9%	Numis Securities Ltd
Mondi	FTSE 250	Basic Materials	Equalweight	920	912	0.9%	Barclays
Admiral Group	FTSE 100	Financial	Equalweight	1369	1378	-0.7%	Barclays
Lancashire Holdings Ltd	FTSE 250	Financial	Equalweight	801	810	-1.1%	Barclays
Legal & General Group	FTSE 100	Financial	Overweight	188	190.6	-1.4%	Barclays
AstraZeneca	FTSE 100	Consumer, Non-cyclical	Equalweight	3215	3265	-1.5%	Barclays
Hiscox Ltd	FTSE 250	Financial	Overweight	590	606	-2.6%	Barclays
Pearson	FTSE 100	Communications	Hold	1192	1255	-5.0%	Numis Securities Ltd
GlaxoSmithKline	FTSE 100	Consumer, Non-cyclical	Overweight	1610	1697.5	-5.2%	Barclays
Resolution Ltd	FTSE 100	Financial	Overweight	296	312.1	-5.2%	Barclays
Old Mutual	FTSE 100	Financial	Equalweight	183	197.1	-7.2%	Barclays
Rolls-Royce Holdings	FTSE 100	Industrial	Market Perform	1100	1195	-7.9%	Sanford C. Bernstein & Co
Reckitt Benckiser Group	FTSE 100	Consumer, Non-cyclical	Sell	4300	4689	-8.3%	Societe Generale
RSA Insurance Group	FTSE 100	Financial	Underweight	116	129	-10.1%	Barclays
Phoenix Group Holdings	FTSE 250	Financial	Underweight	621	722.5	-14.0%	Barclays
Standard Life	FTSE 100	Financial	Underweight	312	381.1	-18.1%	Barclays
Aviva	FTSE 100	Financial	Underweight	294	372.4	-21.1%	Barclays

Source: The data compiled in the table above has been retrieved from Bloomberg (22 July 2013)

## Ratings definitions:

Under perform or Underweight: a security will fare worse than a specific benchmark Upgrades and downgrades: a broker's last rating

Maintain: a broker has maintained or reiterated a recommendation

New ratings: an analyst has initiated coverage on a stock
Neutral or in-line recommendation: the broker expects a security's share price to match the performance of a benchmark

Price targets: the value a contributing broker expects the share price to reach (generally within a 12-month period). Recommendations are not always accompanied by a price target

Last Price: the Market share price at the time of writing the update

Potential upside/downside: the 'potential' percentage gain or loss that could result if a contributing broker's price target is reached. The percentage gain or loss is calculated based on the last price

Contributing broker: refers to the investment management firm providing the recommendation and price target

Disclaimer: IG provides an execution-only service. The material above does not contain (and should not be construed as containing) investment advice or an investment recommendation, or a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of the above information. Consequently any person acting on it does so entirely at his or her own risk. The research does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. This communication must not be reproduced or further distributed.